Skip to main content
Julian Bryan on Muck Rack

Julian Bryan

United Kingdom
As seen in: Nature, lawsociety.org.uk, The Law Society Gazette, Legal Futures, LegalSupportNetwork.co.uk
As Managing Director of Quill, my role is providing software & services which help lawyers overcome daily business management & legal accounting challenges.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Julian

Contact Julian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma

|
By Jack Ghannam, Julian Bryan, Jakob Weiss, Daniel Kovarsky, David Merrell, Conor Messer, Kristy Schlueter-Kuck, Geoffrey G Fell, Mary Jane Lim-Fat, Gilbert Youssef, Rifaquat Rahman, Lei Qin, J. Thomas Janes III, McKayla Van Orden, Kathleen L. Pfaff, Andrew Gans Verified, Emma Lin, Raymond Y. Huang, Brian P. Danysh, Laxmi Parida, Shuqiang Li, Patrick Y Wen, E. Antonio Chiocca, Donna S. Neuberg, Keith L. Ligon, Itay Tirosh, David A Reardon, Gad Getz, Catherine J. Wu
| Nature Verified
Correction to: Nature Cancer https://doi.org/10.1038/s43018-026-01179-2, published online 3 June 2026. In the version of the article initially published, in the Abstract, “we profiled 181 ICB-treated GBM samples with bulk DNA sequencing” should have read “we profiled 181 ICB-treated GBM cases using bulk DNA sequencing”.
Open in Who Shared Issue with article?

Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma

|
By Jack Ghannam, Julian Bryan, Jakob Weiss, Daniel Kovarsky, David Merrell, Conor Messer, Kristy Schlueter-Kuck, Geoffrey G Fell, Mary Jane Lim-Fat, Gilbert Youssef, Rifaquat Rahman, Lei Qin, Kathleen L. Pfaff, Andrew Gans Verified, Emma Lin, Raymond Y. Huang, Brian P. Danysh, Laxmi Parida, Shuqiang Li, Patrick Y Wen, E. Antonio Chiocca, Donna S. Neuberg, Keith L. Ligon, Itay Tirosh, David A Reardon, Gad Getz, Catherine J. Wu, J. Thomas Janes III, McKayla Van Orden
| Nature Verified
Abstract The determinants of immune checkpoint blockade (ICB) response in glioblastoma (GBM) with wild-type isocitrate dehydrogenase remain poorly understood. Here we profiled 181 ICB-treated GBM samples with bulk DNA sequencing, bulk RNA sequencing and single-nucleus RNA sequencing to investigate the genomic features associated with ICB outcomes.
Open in Who Shared Issue with article?

Biomarker, treatment patterns, and survival differences in metastatic triple-negative breast cancer by race in the United States

|
By Samantha Thompson, Clara Lam, Julian Bryan, Pegah Farrokhi, Leah Park, Howard Weston Schmutz, David D. Stenehjem
| Nature Verified
Abstract Triple-negative breast cancer (TNBC) disproportionately affects Black women, with higher incidence rates and worse outcomes compared with White women. This study included 670 adult patients with metastatic TNBC diagnosed between January 2017 and March 2022 from the Flatiron Clinico-Genomic database. All patients underwent NGS-based testing and were assessed for prevalence of BRCA1/2, PIK3CA, AKT1, and PTEN alterations; treatment patterns; and survival outcomes.
Open in Who Shared Issue with article?
See all 18 articles